Johnson and Johnson Gets CDSCO Panel Nod for Talqetamab in Relapsed Multiple Myeloma, Phase IV Trial Mandated
New Delhi: The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has recommended grant of permission to Johnson & Johnson Pvt. Ltd. to import and market…